Tom Soloway

Tom Soloway is the Chief Executive Officer of T-knife Therapeutics, a transatlantic biotech developing T-cell receptor (TCR-T) therapies aimed at solid tumors. With more than 25 years across strategy, operations, corporate finance and venture capital, he has helped build and finance a string of life sciences companies including Transcept Pharmaceuticals, Ascendis Pharma and Audentes Therapeutics. He took the helm of T-knife in January 2021, positioning the Berlin- and San Francisco-based company to move its 'supercharged' TCR-T candidates into the clinic while staying lean and capital-efficient.